News

Teva news, press releases, and media contact information

Press Releases
Keyword Search
 
  
For all global news, visit our corporate site.
12/14/2018Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain IndicationsINCHEON, South Korea & JERUSALEM--(BUSINESS WIRE)--Dec. 14, 2018-- Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industrie... 
11/28/2018Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma IndicationsTRUXIMA® is the first rituximab biosimilar to be approved in the United States INCHEON, South Korea & JERUSALEM--(BUSINESS WIRE)--No... 
11/27/2018Teva’s Generic Version of EpiPen® (Epinephrine Injection, USP) Auto-Injector 0.3 mg Now Available in Limited Quantity in the United StatesPARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 27, 2018-- Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced the release of l... 
11/26/2018Statement: Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within ExpiryTeva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination ... 
11/10/2018Statement: CVS Caremark formulary coverage for AJOVY™ (fremanezumab-vfrm) injectionStatement: CVS Caremark formulary coverage for AJOVY™ (fremanezumab-vfrm) injectionNovember 10, 2018— AJOVY™ (fremanezumab-vfrm) injection will now ... 
11/01/2018Teva Reports Third Quarter 2018 Financial ResultsRevenues of $4.5 billion Free cash flow of $704 million GAAP diluted loss per share of $0.27 ... 
10/17/2018Statement: ESI decision regarding formulary coverage for AJOVY™ (fremanezumab-vfrm) injectionOctober 17, 2018 -- We are confident in the strategic decisions made when establishing the price for AJOVY™ (fremanezumab-vfrm) injection, which is ... 
10/10/2018Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab BiosimilarIf approved, CT-P10, a proposed biosimilar to Rituxan® (rituximab), will be the first rituximab biosimilar to be approved in the United ... 
10/05/2018Teva to Report Third Quarter 2018 Financial Results on November 1, 2018JERUSALEM--(BUSINESS WIRE)--Oct. 5, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will releas... 
09/27/2018Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United StatesJERUSALEM--(BUSINESS WIRE)--Sep. 27, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive fir... 
09/14/2018Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in AdultsJERUSALEM--(BUSINESS WIRE)--Sep. 14, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food... 
09/12/2018Teva to Present at the Morgan Stanley Global Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Sep. 12, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at ... 
08/16/2018Statement: United States Food and Drug Administration Approves Teva’s Generic Epinephrine Injection Auto-InjectorTeva is pleased with the US FDA's approval of its generic versions of EpiPen® and EpiPen Jr ® (epinephrine injection, USP) Auto-Injectors in the US. ... 
08/16/2018Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or HipData include final primary efficacy results and an interim safety analysis JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 16, 20... 
08/06/2018Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United StatesJERUSALEM--(BUSINESS WIRE)--Aug. 6, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food ... 
08/02/2018Teva Reports Second Quarter 2018 Financial ResultsRevenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 ... 
07/17/2018Teva Highlights Key Milestones Achieved in the 2017 Social Impact ReportJERUSALEM--(BUSINESS WIRE)--Jul. 17, 2018-- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social... 
07/16/2018Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide TabletsPARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 5... 
07/11/2018Teva to Report Second Quarter 2018 Financial Results on August 2, 2018JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will release its sec... 
07/09/2018Teva Announces Launch of a Generic Version of Uceris® in the United StatesJERUSALEM--(BUSINESS WIRE)--Jul. 9, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a ge... 
06/28/2018Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific MeetingOne late breaker, three platform presentations and 23 posters showcase fremanezumab as an investigational treatment for the prevention o... 
05/23/2018Teva Confirms September PDUFA Date for FremanezumabJERUSALEM--(BUSINESS WIRE)--May 23, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food ... 
05/15/2018Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical AssociationJERUSALEM--(BUSINESS WIRE)--May 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data fr... 
05/03/2018Teva Reports First Quarter 2018 Financial ResultsRevenues of $5.1 billion Free cash flow of $1.9 billion GAAP EPS of $1.03 N... 
05/02/2018Teva to Present AUSTEDO® (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual MeetingThree abstracts evaluate the long-term safety and efficacy of AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesi... 
04/27/2018Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mLUp to 7-year efficacy, safety and tolerability results from the GALA open-label extension study presented at the 70th Annual Meeting of ... 
04/23/2018Teva to Report First Quarter 2018 Financial Results on May 3, 2018JERUSALEM--(BUSINESS WIRE)--Apr. 23, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fi... 
04/17/2018Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of NeurologyTwo platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention ... 
03/26/2018Teva Announces the Launch of a Generic Version of Lialda® in the United StatesJERUSALEM--(BUSINESS WIRE)--Mar. 26, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a g... 
03/23/2018Teva Announces the Launch of a Generic Version of ALOXI® in the United StatesJERUSALEM--(BUSINESS WIRE)--Mar. 23, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic ve... 
03/12/2018Teva to Present at the Cowen & Company 38th Annual Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Mar. 12, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at ... 
02/21/2018Teva Announces New Brand Positioning and Visual Identity in North AmericaTeva Pharmaceutical is announcing a new brand positioning and visual identity in North America. The new brand will continue to roll out globally throu... 
02/20/2018Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn® in the United StatesJERUSALEM--(BUSINESS WIRE)--Feb. 20, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive lau... 
02/12/2018Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation AerosolFirst and Only Breath-Actuated Aerosol Inhaled Corticosteroid in the United States Designed to Help Eliminate the Need for Hand-Breath C... 
02/09/2018Teva Announces Launch of a Generic Version of Syprine® in the United StatesJERUSALEM--(BUSINESS WIRE)--Feb. 9, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of gene... 
02/08/2018Teva Reports 2017 Full Year and Fourth Quarter Financial ResultsJERUSALEM--(BUSINESS WIRE)--Feb. 8, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the q... 
01/25/2018Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results at 8 a.m. ET on February 8, 2018JERUSALEM--(BUSINESS WIRE)--Jan. 25, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will issue a press ... 
01/15/2018Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic LeukemiaJERUSALEM--(BUSINESS WIRE)--Jan. 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and D... 
01/08/2018Teva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based TherapyJERUSALEM--(BUSINESS WIRE)--Jan. 8, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that its subsidiary... 
01/04/2018Teva to Present at the 36th Annual J.P. Morgan Healthcare ConferenceJERUSALEM--(BUSINESS WIRE)--Jan. 4, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 36th A... 
01/02/2018Teva Announces Launch of an Authorized Generic of Estrace® Cream in the United StatesJERUSALEM--(BUSINESS WIRE)--Jan. 2, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an a...